- Home
- APLM vs STRR Comparison
APLM vs STRR Comparison
Compare APLM & STRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- STRR
- Stock Information
- Founded
- APLM 2016
- STRR 1985
- Country
- APLM United States
- STRR United States
- Employees
- APLM N/A
- STRR N/A
- Industry
- APLM Blank Checks
- STRR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- APLM Finance
- STRR Health Care
- Exchange
- APLM Nasdaq
- STRR Nasdaq
- Market Cap
- APLM 7.7M
- STRR 6.3M
- IPO Year
- APLM N/A
- STRR N/A
- Fundamental
- Price
- APLM $6.51
- STRR $1.99
- Analyst Decision
- APLM Strong Buy
- STRR
- Analyst Count
- APLM 1
- STRR 0
- Target Price
- APLM $200.00
- STRR N/A
- AVG Volume (30 Days)
- APLM 57.8K
- STRR 13.4K
- Earning Date
- APLM 04-03-2025
- STRR 05-19-2025
- Dividend Yield
- APLM N/A
- STRR N/A
- EPS Growth
- APLM N/A
- STRR N/A
- EPS
- APLM N/A
- STRR N/A
- Revenue
- APLM $198,000.00
- STRR $53,359,000.00
- Revenue This Year
- APLM $415.15
- STRR $43.37
- Revenue Next Year
- APLM N/A
- STRR $23.60
- P/E Ratio
- APLM N/A
- STRR N/A
- Revenue Growth
- APLM N/A
- STRR 16.54
- 52 Week Low
- APLM $4.71
- STRR $1.72
- 52 Week High
- APLM $53.00
- STRR $5.35
- Technical
- Relative Strength Index (RSI)
- APLM 49.37
- STRR 44.79
- Support Level
- APLM $5.41
- STRR $1.72
- Resistance Level
- APLM $6.19
- STRR $2.14
- Average True Range (ATR)
- APLM 0.77
- STRR 0.14
- MACD
- APLM 0.08
- STRR -0.02
- Stochastic Oscillator
- APLM 95.24
- STRR 42.86
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About STRR Star Equity Holdings Inc.
Star Equity Holdings Inc is a multi-industry diversified holding company. It operates in two segments: Building Solutions segment, through KBS, EBGL and TT, it services residential and commercial construction projects by manufacturing modular housing units, structural wall panels, permanent wood foundation systems, other engineered wood products, and supply general contractors with building materials; and Investments segment, which holds corporate-owned real estate, currently includes one manufacturing facility and the equipment for another manufacturing facility in Maine that it leases back to KBS and its manufacturing facility in Wisconsin that it leases back to TT. The company derives maximum revenue from Building Solutions Segment.